Suchergebnisse - "Kazandjian, Dickran"

PubPharm (13)

1

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

enthalten in: Nature cancer | 2023

von Maura, F. | Boyle, E. | Coffey, D. | +34

2

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

enthalten in: Nature communications | 2023

von Coffey, D. | Maura, F. | Gonzalez-Kozlova, E. | +20

3

Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma : pooled analysis of four single-arm studies

enthalten in: Leukemia & lymphoma | 2022

von Landgren, O. | Kazandjian, D. | Roussel, M. | +7

4

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma : A Phase 2 Nonrandomized Controlled Trial

enthalten in: JAMA oncology | 2021

von Kazandjian, D. | Hill, E. | Dew, A. | +31

5

Treatments for newly diagnosed multiple myeloma : when endurance is interrupted

enthalten in: The Lancet. Oncology | 2020

von Landgren, O. | Siegel, D. | Kazandjian, D. | +2

CommentOn: Lancet Oncol. 2020 Oct;21(10):1317-1330. - PMID 32866432

6

Second malignancies in multiple myeloma; emerging patterns and future directions

enthalten in: Best practice & research. Clinical haematology | 2020

von Maclachlan, K. | Diamond, B. | Maura, F. | +4

7

The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!

enthalten in: Best practice & research. Clinical haematology | 2020

von Kazandjian, D. | Dew, A. | Hill, E.

8

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

enthalten in: Scientific reports | 2019

von Huang, P. | Beedie, S. | Chau, C. | +7

9

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone : Five-Year Follow-up of a Phase 2 Clinical Trial

enthalten in: JAMA oncology | 2018

von Kazandjian, D. | Korde, N. | Mailankody, S. | +4

10

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

enthalten in: Bone marrow transplantation | 2018

von Tageja, N. | Korde, N. | Kazandjian, D. | +10